Trevi Therapeutics (TRVI) Change in Account Payables (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Change in Account Payables of -$1.5 million for Q1 2026, up 25.59% year-over-year from -$1.2 million in Q1 2025, and down 1305.69% quarter-over-quarter from $123000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Change in Account Payables (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Change in Account Payables history runs 9 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 25.59% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$88000.0 (up 87.1% YoY), while the FY2025 annual figure was -$598000.0, down 137.26% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1.5 million, down from $123000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.1 million in Q2 2022, with the low at -$2.0 million in Q1 2025.
- The 5-year median for Change in Account Payables is -$170000.0 (2023), against an average of -$89176.5.
- Peak annual rise in Change in Account Payables reached 351.46% in 2025, while the deepest fall reached 777.89% in 2025.
- Trevi Therapeutics' Change in Account Payables stood at $536000.0 in 2022, then increased by 16.98% to $627000.0 in 2023, then surged by 186.92% to $1.8 million in 2024, then slumped by 93.16% to $123000.0 in 2025, then plunged by 1305.69% to -$1.5 million in 2026.
- Business Quant data shows TRVI's Change in Account Payables at -$1.5 million in Q1 2026, $123000.0 in Q4 2025, and -$282000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | -276,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -276,000.00 |
| Mar 31, 2026 | -1.48 Mn |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | -618,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Dec 31, 2023 | 627,000.00 |
| Sep 30, 2023 | -170,000.00 |
| Jun 30, 2023 | -592,000.00 |
| Mar 31, 2023 | -914,000.00 |
| Dec 31, 2022 | 536,000.00 |
| Sep 30, 2022 | -1.47 Mn |
| Jun 30, 2022 | 2.05 Mn |
| Mar 31, 2022 | -1.11 Mn |
| Dec 31, 2021 | 615,000.00 |
| Sep 30, 2021 | -1.26 Mn |